Ignite Creation Date:
2024-05-05 @ 10:20 PM
Last Modification Date:
2024-10-26 @ 10:17 AM
Study NCT ID:
NCT01082887
Status:
TERMINATED
Last Update Posted:
2016-08-08
First Post:
2010-03-08
Brief Title:
A Study of Immunotherapy With TIL Tumor Infiltrating Lymphocytes in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus Ad-IFNg in Patients With Stage IIIc or Stage IV Metastatic Melanoma AJCCProtocol TIL-Ad-INFg
Sponsor:
Nantes University Hospital
Organization:
Nantes University Hospital
Study Overview
Official Title:
A Phase III Study of Immunotherapy With TIL Tumor Infiltrating Lymphocytes in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus Ad-IFNg in Patients With Stage IIIc or Stage IV Metastatic Melanoma AJCC
Status:
TERMINATED
Status Verified Date:
2016-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objective of this study is to evaluate the clinical and biologic toxicity of cell therapy by adoptive transfer of TIL in combination with intra-tumoral injections of Ad-INFg
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2009-013087-38 | EUDRACT_NUMBER | None | None |